PLATFORM

Elixiron is transforming the treatment of immune-mediated diseases through precision immunotherapy, targeting the unique drivers of immune dysfunction in each condition. Leveraging cutting-edge research, we uncover intricate immune pathways and key biomarkers to develop therapies that address the root causes of disease. This innovative approach delivers more effective, targeted treatments, redefining care and offering new hope for individuals affected by immune-mediated conditions.

Elixiron's state-of-the-art mRNA drug development platform is revolutionizing biologic therapies by enabling in vivo protein expression and accelerating the transition from research to clinical application. Leveraging mRNA as a precise expression modality, this platform directs cells to produce therapeutic proteins within the body, overcoming traditional limitations and delivering highly targeted and efficient treatments. Its flexibility supports diverse applications, ranging from cancer immunotherapy to genetic modification, while dramatically reducing development time and costs, setting new standards in innovative patient care.

Elixiron accelerates the development of fully human antibody therapeutics through its novel antibody discovery platform. At its core, single B cell cloning technology recovers high-affinity, low-immunogenicity antibody sequences directly from affinity-matured human immune responses, followed by sequence optimization to enhance developability. For novel targets lacking a natural immune response, AI-assisted synthetic human antibody libraries combined with phage display enable high-throughput screening. Together, these complementary routes have delivered multiple antibody candidates that have advanced into clinical development and been successfully out-licensed, demonstrating the platform's ability to translate discovery into clinical value.